Abstract
Background: Preeclampsia, a gestational disease characterized by hypertension and proteinuria twenty weeks into pregnancy, is one of the leading causes of fetal and maternal mortality. Although multiple genetic and environmental factors are found to be related to the preeclampsia risk, the pathogenic pathways remain largely undefined. The placenta plays a critical role in the fetal development by carrying out the barrier, fetal-maternal exchange, and endocrine functions during pregnancy. Accumulated data indicated that the expression of multiple long noncoding RNA (LncRNA) is dysregulated in preeclamptic placentas. Moreover, manipulation of LncRNA expression led to functional alterations in trophoblast cell cultures, including changes in proliferation, differentiation, apoptosis, and migration.
Objective: This article reviews published data on this subject and provides detailed information on the regulation and function of LncRNAs IGF2/H19, MEG3, SPRY4-IT1, HOTAIR, MALAT1, and FLT1P1 and CEACAMP8 in placental trophoblasts. The potential mechanisms underlying the action of these LncRNAs are also discussed to facilitate a better understanding on the potential role of these LncRNAs for the pathogenesis of preeclampsia. Conclusion: It is elaborated that some lncRNAs probably contribute to the pathogenesis of preeclampsia through methylation, Notch-EGFL7 signaling pathway and Wnt/β-catenin pathway.Keywords: Preeclampsia, non-coding RNA, LncRNA, trophoblast, placenta, pathogenesis.
Current Drug Targets
Title:Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Volume: 18 Issue: 10
Author(s): Xuejing Song, Xiucui Luo, Quansheng Gao, Yuhuan Wang, Qing Gao and Wei Long*
Affiliation:
- Department of Obstetrics, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing,China
Keywords: Preeclampsia, non-coding RNA, LncRNA, trophoblast, placenta, pathogenesis.
Abstract: Background: Preeclampsia, a gestational disease characterized by hypertension and proteinuria twenty weeks into pregnancy, is one of the leading causes of fetal and maternal mortality. Although multiple genetic and environmental factors are found to be related to the preeclampsia risk, the pathogenic pathways remain largely undefined. The placenta plays a critical role in the fetal development by carrying out the barrier, fetal-maternal exchange, and endocrine functions during pregnancy. Accumulated data indicated that the expression of multiple long noncoding RNA (LncRNA) is dysregulated in preeclamptic placentas. Moreover, manipulation of LncRNA expression led to functional alterations in trophoblast cell cultures, including changes in proliferation, differentiation, apoptosis, and migration.
Objective: This article reviews published data on this subject and provides detailed information on the regulation and function of LncRNAs IGF2/H19, MEG3, SPRY4-IT1, HOTAIR, MALAT1, and FLT1P1 and CEACAMP8 in placental trophoblasts. The potential mechanisms underlying the action of these LncRNAs are also discussed to facilitate a better understanding on the potential role of these LncRNAs for the pathogenesis of preeclampsia. Conclusion: It is elaborated that some lncRNAs probably contribute to the pathogenesis of preeclampsia through methylation, Notch-EGFL7 signaling pathway and Wnt/β-catenin pathway.Export Options
About this article
Cite this article as:
Song Xuejing, Luo Xiucui, Gao Quansheng, Wang Yuhuan, Gao Qing and Long Wei*, Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170404160000
DOI https://dx.doi.org/10.2174/1389450118666170404160000 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Contraception in Women with Medical Conditions
Current Women`s Health Reviews Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Therapeutic Targets to Raise HDL in Patients at Risk or with Coronary Artery Disease
Current Vascular Pharmacology On the Role of Endothelial TRPC3 Channels in Endothelial Dysfunction and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy
Current Drug Safety Novel High Throughput Polymer Biocompatibility Screening Designed for SAR (Structure-Activity Relationship): Application for Evaluating Polymer Coatings for Cardiovascular Drug-Eluting Stents
Combinatorial Chemistry & High Throughput Screening Acute Cerebral Blood Flow Variations after Human Cardiac Arrest Assessed by Stable Xenon Enhanced Computed Tomography
Current Neurovascular Research Insulin Resistance is Associated with Clinical Manifestations of Diabetic Kidney Disease (Glomerular Hyperfiltration, Albuminuria, and Kidney Function Decline)
Current Diabetes Reviews Role of Chronotherapy in the Management of Hypertension: An Overview
Current Drug Therapy Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure
Cardiovascular & Hematological Disorders-Drug Targets Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions
Current Pharmaceutical Design A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action
Current Medicinal Chemistry Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine